by Valentine Chervonenko | Mar 11, 2026 | Uncategorized
The 30-respondent pharmaceutical research tradition: understanding where it shines and where it can leave you exposed. By DOCREPLAY.ai ABSTRACT Most pharmaceutical brand teams default to 30 respondents for qualitative research because it’s the industry standard...
by Valentine Chervonenko | Mar 11, 2026 | Uncategorized
More voices, better decisions:Why the volume of physician and patientresponses matters more than you think. By DOCREPLAY.ai ABSTRACT Traditional qualitative pharmaceutical research has long operated within the constraints of in-person, moderated physician interviews –...
by Valentine Chervonenko | Mar 11, 2026 | Uncategorized
Beyond 30:Why the industry standard sample size inpharmaceutical qualitative research isleaving insights on the table. By DOCREPLAY.ai ABSTRACT For decades, pharmaceutical qualitative research has operated on a near-universal assumption: 30 respondents is enough. This...
by Valentine Chervonenko | Mar 11, 2026 | Uncategorized
Speed as Strategy:Why research velocity is a competitiveadvantage in pharmaceutical branddecision-making. By DOCREPLAY.ai ABSTRACT “Speed is the new currency of business.” Marc Benioff said this at the World Economic Forum, and while he was speaking about business...
by Valentine Chervonenko | Mar 9, 2026 | Uncategorized
Making sense of the AI researchlandscape: a practical guide for marketresearch leaders navigating AI-poweredqualitative methodologies. By DOCREPLAY.ai ABSTRACT The pharmaceutical market research industry is undergoing a seismic shift. Artificial intelligence has moved...
